Favorable α‐fetoprotein decrease as a prognostic surrogate in patients with hepatocellular carcinoma after radiofrequency ablation

Publisher： John Wiley & Sons Inc

E-ISSN： 1440-1746|25|3|605-612

ISSN： 0815-9319

Source： JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol.25, Iss.3, 2010-03, pp. : 605-612

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Early Decrease in α-Fetoprotein, but Not Des-γ-Carboxy Prothrombin, Predicts Sorafenib Efficacy in Patients with Advanced Hepatocellular Carcinoma

By  

Oncology, Vol. 81, Iss. 3-4, 2011-11 ,pp. : 251-258

Karger

Access to resources Recommend Favorite

PIVKA-II Is the Best Prognostic Predictor in Patients with Hepatocellular Carcinoma after Radiofrequency Ablation Therapy

By  

Oncology, Vol. 75, Iss. 1, 2008-12 ,pp. : 91-98

Karger

Access to resources Recommend Favorite

Clinical significance of half‐lives of tumor markers α‐fetoprotein and des‐γ‐carboxy prothrombin after hepatectomy for hepatocellular carcinoma

By  

HEPATOLOGY RESEARCH, Vol. 48, Iss. 3, 2018-02 ,pp. : E183-E193

John Wiley & Sons Inc

Access to resources Recommend Favorite

Evaluation of the mRECIST and α-Fetoprotein Ratio for Stratification of the Prognosis of Advanced-Hepatocellular-Carcinoma Patients Treated with Sorafenib

By  

Oncology, Vol. 83, Iss. 4, 2012-08 ,pp. : 192-200

Karger

Access to resources Recommend Favorite

Prediction of risk for hepatocellular carcinoma by response of serum α‐fetoprotein to entecavir therapy

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 30, Iss. 7, 2015-07 ,pp. : 1175-1182

John Wiley & Sons Inc

Access to resources Recommend Favorite